suramin has been researched along with Glioblastoma in 6 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in glioma progression, angiogenesis, and radioresistance." | 6.71 | Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. ( Carson, KA; Gilbert, MR; Grossman, SA; Hochberg, FH; Laterra, JJ; Lesser, GJ, 2004) |
| " Additionally, we compared the antitumoral effect of protamine with that of another inhibitor of angiogenesis, suramin, and investigated a potential synergistic antitumoral action of low doses of protamine combined with the antineoplastic carmustine." | 5.30 | Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. ( Arrieta, O; Guevara, P; Ortiz, A; Rembao, D; Reyes, S; Sotelo, J, 1998) |
| "Suramin is a novel anticancer agent that blocks the binding of growth factors, including basic fibroblast growth factor (bFGF), to their receptors." | 5.29 | Suramin inhibits glioma cell proliferation in vitro and in the brain. ( Brem, S; Engelhard, H; Gately, S; Takano, S; Tsanaclis, AM, 1994) |
| "Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in glioma progression, angiogenesis, and radioresistance." | 2.71 | Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. ( Carson, KA; Gilbert, MR; Grossman, SA; Hochberg, FH; Laterra, JJ; Lesser, GJ, 2004) |
| " Additionally, we compared the antitumoral effect of protamine with that of another inhibitor of angiogenesis, suramin, and investigated a potential synergistic antitumoral action of low doses of protamine combined with the antineoplastic carmustine." | 1.30 | Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. ( Arrieta, O; Guevara, P; Ortiz, A; Rembao, D; Reyes, S; Sotelo, J, 1998) |
| "Trapidil and suramin inhibit this growth factor-stimulated glioma cell growth, but the mechanisms are not fully understood." | 1.29 | Effects of trapidil and suramin on growth factor-induced calcium response and tyrosine phosphorylation in human glioma cells. ( Bando, K; Kannuki, S; Matsumoto, K; Rokutan, K; Shouno, M, 1995) |
| "Suramin is a novel anticancer agent that blocks the binding of growth factors, including basic fibroblast growth factor (bFGF), to their receptors." | 1.29 | Suramin inhibits glioma cell proliferation in vitro and in the brain. ( Brem, S; Engelhard, H; Gately, S; Takano, S; Tsanaclis, AM, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laterra, JJ | 1 |
| Grossman, SA | 1 |
| Carson, KA | 1 |
| Lesser, GJ | 1 |
| Hochberg, FH | 1 |
| Gilbert, MR | 1 |
| Bando, K | 1 |
| Kannuki, S | 1 |
| Rokutan, K | 1 |
| Shouno, M | 1 |
| Matsumoto, K | 1 |
| Takano, S | 1 |
| Gately, S | 1 |
| Engelhard, H | 1 |
| Tsanaclis, AM | 1 |
| Brem, S | 1 |
| Arrieta, O | 1 |
| Guevara, P | 1 |
| Reyes, S | 1 |
| Ortiz, A | 1 |
| Rembao, D | 1 |
| Sotelo, J | 1 |
| de Joannon, AC | 1 |
| Mancini, F | 1 |
| Landolfi, C | 1 |
| Soldo, L | 1 |
| Leta, A | 1 |
| Ruggieri, A | 1 |
| Mangano, G | 1 |
| Polenzani, L | 1 |
| Pinza, M | 1 |
| Milanese, C | 1 |
| Hosoi, Y | 1 |
| Matsumoto, Y | 1 |
| Tomita, M | 1 |
| Enomoto, A | 1 |
| Morita, A | 1 |
| Sakai, K | 1 |
| Umeda, N | 1 |
| Zhao, HJ | 1 |
| Nakagawa, K | 1 |
| Ono, T | 1 |
| Suzuki, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Suramin and Concurrent Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme[NCT00004073] | Phase 2 | 54 participants (Anticipated) | Interventional | 1999-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for suramin and Glioblastoma
| Article | Year |
|---|---|
Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study.
Topics: Aged; Brain Neoplasms; Confidence Intervals; Female; Follow-Up Studies; Glioblastoma; Humans; Male; | 2004 |
5 other studies available for suramin and Glioblastoma
| Article | Year |
|---|---|
Effects of trapidil and suramin on growth factor-induced calcium response and tyrosine phosphorylation in human glioma cells.
Topics: Antineoplastic Agents; Calcium; Cell Division; Epidermal Growth Factor; Glioblastoma; Humans; Phosph | 1995 |
Suramin inhibits glioma cell proliferation in vitro and in the brain.
Topics: Animals; Brain Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Screening Assays, An | 1994 |
Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dose-Response Relationship, D | 1998 |
Adenosine triphosphate affects interleukin -1beta release by T98G glioblastoma cells through a purinoceptor-independent mechanism.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cell Membrane; Dose-Response Relationship, Drug; Glio | 2000 |
Phosphorothioate oligonucleotides, suramin and heparin inhibit DNA-dependent protein kinase activity.
Topics: Antineoplastic Agents; Cell Culture Techniques; DNA Damage; DNA Repair; DNA-Activated Protein Kinase | 2002 |